Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

10.04.2023

1 Ann N Y Acad Sci
1 BMJ
3 Clin Infect Dis
1 J Gen Virol
2 J Infect
3 J Infect Dis
1 JAMA
1 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 Pediatrics
5 PLoS One
1 Science
23 Vaccine
1 Virology


    Ann N Y Acad Sci

  1. CABLE J, Graham BS, Koup RA, Seder RA, et al
    Progress in vaccine development for infectious diseases-a Keystone Symposia report.
    Ann N Y Acad Sci. 2023 Apr 5. doi: 10.1111/nyas.14975.
    >> Share


    BMJ

  2. BARNES-WEISE J, Hoemeke L, Telford B
    Public investment in the development of vaccines: providing equitable access around the world.
    BMJ. 2023;381:p743.
    >> Share


    Clin Infect Dis

  3. MARKS KM, Kang M, Umbleja T, Avihingsanon A, et al
    Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV.
    Clin Infect Dis. 2023 Apr 5:ciad201. doi: 10.1093.
    >> Share

  4. LEVIN MJ, Ustianowski A, Thomas S, Templeton A, et al
    AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19.
    Clin Infect Dis. 2022 Nov 22:ciac899. doi: 10.1093.
    >> Share

  5. BLOSSEY AM, Bruckner S, May M, Parzmair GP, et al
    VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical study.
    Clin Infect Dis. 2022 Nov 11. pii: 6821343. doi: 10.1093.
    >> Share


    J Gen Virol

  6. VAZ PK, Armat M, Hartley CA, Devlin JM, et al
    Codon pair bias deoptimization of essential genes in infectious laryngotracheitis virus reduces protein expression.
    J Gen Virol. 2023;104.
    >> Share


    J Infect

  7. NYGREN TM, Pilic A, Bohmer MM, Wagner-Wiening C, et al
    Tick-borne encephalitis: Acute clinical manifestations and severity in 581 cases from Germany, 2018-2020.
    J Infect. 2023;86:369-375.
    >> Share

  8. EVANS A, Qi C, Adebayo JO, Underwood J, et al
    Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
    J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.
    >> Share


    J Infect Dis

  9. TANG L, Wang FZ, Rodewald LE, Wang XY, et al
    Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
    J Infect Dis. 2023 Apr 3:jiad090. doi: 10.1093.
    >> Share

  10. EL-HENEIDY A, Grimwood K, Lambert SB, Ware RS, et al
    Interference between enteric viruses and live-attenuated rotavirus vaccine virus in a healthy Australian birth cohort.
    J Infect Dis. 2023 Apr 4:jiad094. doi: 10.1093.
    >> Share

  11. BLANKSON JN
    Bivalent COVID Vaccines; Can the Original Antigenic Sin be Forgiven?
    J Infect Dis. 2023 Apr 5:jiad073. doi: 10.1093.
    >> Share


    JAMA

  12. AMMIRATI E, Moslehi JJ
    Diagnosis and Treatment of Acute Myocarditis: A Review.
    JAMA. 2023;329:1098-1113.
    >> Share


    MMWR Morb Mortal Wkly Rep

  13. BIGOUETTE JP, Henderson E, Traore MA, Wassilak SGF, et al
    Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:366-371.
    >> Share


    N Engl J Med

  14. KAMPMANN B, Madhi SA, Munjal I, Simoes EAF, et al
    Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
    N Engl J Med. 2023 Apr 5. doi: 10.1056/NEJMoa2216480.
    >> Share

  15. WALSH EE, Perez Marc G, Zareba AM, Falsey AR, et al
    Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    N Engl J Med. 2023 Apr 5. doi: 10.1056/NEJMoa2213836.
    >> Share


    Pediatrics

  16. KLEIN NP, Demarco M, Fleming-Dutra KE, Stockwell MS, et al
    Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
    Pediatrics. 2023 Apr 7:e2022060894. doi: 10.1542/peds.2022-060894.
    >> Share


    PLoS One

  17. GOLOS AM, Guntuku SC, Piltch-Loeb R, Leininger LJ, et al
    Dear Pandemic: A topic modeling analysis of COVID-19 information needs among readers of an online science communication campaign.
    PLoS One. 2023;18:e0281773.
    >> Share

  18. MOHANTY S, Podmore B, Cunado Moral A, Matthews I, et al
    Healthcare resource utilisation and cost of pneumococcal disease from 2003 to 2019 in children
    PLoS One. 2023;18:e0283084.
    >> Share

  19. KRAUTMANN M, Davis B, Leroueil PR
    A model for estimating costs and benefits of new vaccine technologies from the perspective of both buyers and sellers.
    PLoS One. 2023;18:e0283977.
    >> Share

  20. DOUCETTE EJ, Gray J, Fonseca K, Charlton C, et al
    A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.
    PLoS One. 2023;18:e0284046.
    >> Share

  21. LI J, Nakagawa T, Kojima M, Nishikimi A, et al
    Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study.
    PLoS One. 2023;18:e0283658.
    >> Share


    Science

  22. OFFERSGAARD A, Bukh J, Gottwein JM
    Toward a vaccine against hepatitis C virus.
    Science. 2023;380:37-38.
    >> Share


    Vaccine

  23. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  24. MACHIDA M, Inoue S
    Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study.
    Vaccine. 2023 Apr 4:S0264-410X(23)00355-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  25. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  26. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  27. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    >> Share

  28. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    >> Share

  29. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2023;41 Suppl 1:A105-A112.
    >> Share

  30. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    >> Share

  31. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    >> Share

  32. AFSAR A, Mallya A, Mohammed AAG, Anand S, et al
    Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Vaccine. 2023;41 Suppl 1:A79-A84.
    >> Share

  33. HEMPEL K, McDonald W, Osgood ND, Fisman D, et al
    Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study.
    Vaccine. 2023;41:2430-2438.
    >> Share

  34. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    >> Share

  35. STEIN-ZAMIR C, Shoob H, Abramson D
    Measles clinical presentation, hospitalization and vaccination status among children in a community-wide outbreak.
    Vaccine. 2023 Mar 29:S0264-410X(23)00337-7. doi: 10.1016/j.vaccine.2023.
    >> Share

  36. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  37. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  38. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  39. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  40. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    >> Share

  41. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  42. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  43. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  44. PRASAD N, Stoecker C, Xing W, Cho BH, et al
    Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Vaccine. 2023 Apr 1:S0264-410X(23)00338-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  45. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    >> Share


    Virology

  46. ZHANG Z, Yao F, Lv J, Ding Y, et al
    Identification of B-cell epitopes on structural proteins VP1 and VP2 of Senecavirus A and development of a multi-epitope recombinant protein vaccine.
    Virology. 2023;582:48-56.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016